Skip to content

Cerclage for the Reduction of Extreme Preterm Birth in Twin Pregnancies With a Short Cervix or Dilatation

The Effectiveness of Cerclage for the Reduction of Extreme Preterm Birth and Perinatal Mortality in Twin Pregnancies With a Short Cervix or Dilatation

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05968794
Acronym
TWIN Cerclage
Enrollment
238
Registered
2023-08-01
Start date
2023-05-15
Completion date
2028-12-01
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Birth

Keywords

Preterm birth, Twin pregnancy, Cerclage

Brief summary

The goal of this clinical trial is to assess the effectiveness of a cerclage in women with a twin pregnancy with a midpregnancy short cervix or cervical dilatation compared to standard treatment (no cerclage) in the prevention of extreme preterm birth \< 28 weeks of gestational age. The main question it aims to answer is: What is the effectiveness of a cerclage in women with a twin pregnancy with a midpregnancy short cervix or cervical dilatation compared to standard treatment (no cerclage) in the prevention of extreme preterm birth \< 28 weeks of gestational age? Participants will be randomly assigned to the intervention (cerclage) or comparison (no cerclage) group.

Detailed description

Rationale: In the Netherlands, 250 women with a twin pregnancy deliver at \< 28 weeks per year, resulting in 157 perinatal deaths. A vaginal cerclage could be an effective surgical method to reduce cervical insufficiency and with that preterm birth, but the evidence regarding its effectiveness on extreme preterm birth and (long term) neonatal outcome is lacking. Objective: To assess the effectiveness of a cerclage in women with a twin pregnancy with a midpregnancy short cervix or cervical dilatation compared to standard treatment (no cerclage) in the prevention of extreme preterm birth \< 28 weeks of gestational age. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: A vaginal cerclage is a minor and safe surgical procedure commonly performed in singleton pregnancies with a short cervix and a previous preterm birth in all the participating centers, thus there is experience in the participating hospitals. The results of this study will show whether a vaginal cerclage reduces extreme preterm birth in women with twin pregnancy and a short cervix, and its accompanying perinatal complications. If proven effective, the implementation of this intervention will have a huge impact on the lifelong health of these children and their families.

Interventions

A vaginal cerclage is a short and minor surgical procedure performed under general or regional anesthesia. An unabsorbable suture is placed around/through the cervix to close the cervical canal and to increase its firmness, in order to reduce cervical insufficiency.

Sponsors

ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Participants and investigators will not be blinded for the intervention.

Intervention model description

International, multicenter randomized controlled trial

Eligibility

Sex/Gender
FEMALE
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Women (\> 16 years of age) with a twin pregnancy and: * an asymptomatic short cervix at routine ultrasound investigation (below 24 weeks of gestation) OR * cervical dilatation (below 24 weeks of gestation)

Exclusion criteria

* Women with a mono-amniotic twin pregnancy * Women with twin pregnancy in which one or both children are diagnosed with a major structural, congenital or chromosomal abnormality that is likely to influence the composite adverse neonatal outcome. * Women with dilatation of the cervix and signs of clinical intra-uterine infection, defined by the presence of fever ≥ 38 degrees Celsius. * Women with overt symptoms of preterm labour at time of measurement of short cervix (regular contractions, PPROM, recurrent blood loss). * Women with a placenta previa, defined as a placenta position covering the internal ostium of the cervix. * Women who do not master the Dutch of English language and therefore not able to give written consent

Design outcomes

Primary

MeasureTime frame
Rate of extreme preterm birth<28 weeks of gestation

Secondary

MeasureTime frameDescription
Rate of Preterm birth<24, <32, <34 and <37 weeksIndicated and spontaneous
Rate of Premature rupture of membranesUp to 42 weeks of pregnancy
Gestational age at deliveryAt delivery
Days on ventilation supportUp to 3 months corrected ageNeonatal
Days in NICUUp to 3 months corrected ageNeonatal
Maternal quality of life assessed by the 'European Quality of life 5-Dimension 5-Level' scoreUp to 3 months corrected ageThe 'European Quality of life 5-Dimension 5-Level' score consists of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) that are rated using five levels (no problems (1), slight problems (2), moderate problems (3), severe problems (4), extreme problems (5)). A unique health state is defined by combining one level from each of the five dimensions. Each state is referred to by a 5-digit code, The best score is 11111 and the worst score is 55555.
Rate of maternal outcomesUp to 3 months corrected ageSepsis, need for antibiotics, need to remove cerclage in operation room, mode of delivery (% caesarean delivery).
Adverse neonatal outcomeUp to 3 months corrected ageA composite for adverse neonatal outcome (including bronchopulmonary dysplasia, periventricular leucomalacia \> grade 1, intraventricular hemorrhage \> grade 2, necrotizing enterocolitis \> stage 2, retinopathy of prematurity \> stage 2, proven sepsis and perinatal death)
Number of neonates with proven sepsisUp to 3 months corrected age
Perinatal deathUp to 3 months corrected age
Number of neonates with bronchopulmonary dysplasiaUp to 3 months corrected age
Number of neonates with periventricular leucomalacia > grade 1Up to 3 months corrected age
Number of neonates with intraventricular hemorrhage > grade 2Up to 3 months corrected age
Number of neonates with necrotizing enterocolitis > stage 2Up to 3 months corrected age
Number of neonates with retinopathy of prematurity > stage 2Up to 3 months corrected age

Other

MeasureTime frameDescription
Healthcare costs assessed by the 'iMTA Medical Consumption Questionnaire'Up to one week after labour and up to 3 months corrected ageCosts will be measured from a societal perspective using a web-based questionnaires based on the 'iMTA Medical Consumption Questionnaire'. The scoring involves quantifying the reported healthcare resource use based on the responses provided by the participants. The questionnaire collects information about various types of healthcare services and resources, such as hospitalizations, outpatient visits and medication use.
Healthcare costs assessed by the 'iMTA Productivity Cost Questionnaire'Up to one week after labour and up to 3 months corrected ageCosts will be measured using a web-based questionnaires based on the 'iMTA Productivity Cost Questionnaire'. It collects information on the duration and frequency of productivity loss, as well as associated costs.The questionnaire consists of multiple sections and items that gather data on work-related activities, job characteristics, and productivity impact. Respondents are asked to report on their own productivity or that of a specific population (e.g., patients, caregivers) over a defined period.

Countries

Belgium, Netherlands

Contacts

Primary ContactLissa van gils, MD
TWINC@amsterdamumc.nl+31642811240
Backup ContactMartijn A Oudijk, MD, PhD, Prof
TWINC@amsterdamumc.nl

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026